CROMA-PHARMA
31.5.2021 17:12:04 CEST | Business Wire | Press release
Croma-Pharma (Croma) is opening a new chapter and expanding its product portfolio to meet the growing needs of its customers. With the innovative skincare brand Croma farewell™, the company is specifically addressing the desire of consumers for natural, effective and individual skincare and building upon its many years of experience in the production of hyaluronic acid. The name says it all: consumers say goodbye to their facial skin problems and hello to their new selves when using Croma farewell™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210531005179/en/
The Austrian produced brand will initially launch in all key markets with facial serums for five specific skin types.
High-quality care for specific skin conditions based on hyaluronic acid
Genetics, external factors and psychological influences can have a decisive impact on an individual’s skin condition and lead to various problems. Croma viewed this situation as an opportunity to develop a high-quality facial care line for specific skin needs: Croma farewell™.
The Croma farewell™ cosmetic portfolio of five different facial serums unites carefully selected ingredients with years of experience in the pharmaceutical and aesthetic field. Based on this expertise, all formulations contain a blend of both high and low molecular weight hyaluronic acid – an antioxidant that moisturizes and hydrates the skin, improves elasticity and smoothes and plumps the skin’s appearance to reduce fine lines and wrinkles.
All ingredients incorporated into the serums are carefully selected and based on scientific data to achieve the most effective results.
"With the launch of Croma farewell™, we are strengthening our focus on personalized skincare innovation, drawing on our many years of expertise as well as the latest scientific findings. Croma farewell™ meets the high standard of our medical products and perfectly complements our existing portfolio", explains Managing Director, Andreas Prinz.
Concentrated efficacy: 5 serums for 5 common facial skin conditions
-
farewell irritated skin: Target-specific face serum for irritated, sensitive skin with Hyaluronic Acid, Madecassoside, Niacinamide and D-Panthenol to sooth irritations, reduce skin redness and strengthen the skin barrier.
Perfume free. 30 ml.
-
farewell puffy eyes: A face serum, especially designed for the eye contour, to fight the appearances of puffiness, dark circles and crow's feet. The diligent formulation contains Hyaluronic Acid, D-Panthenol and a complex of Ash tree bark extract, organic silicon and Vitamin B3 for radiant, glowing skin and a fresher look.
Perfume free. 30 ml.
-
farewell dry skin: farewell dry skin contains hydrating ingredients including Hyaluronic Acid, Niacinamide, D-Panthenol and Aloe Vera to effectively nourish the skin and strengthen the skin barrier. Softens the skin and boosts elasticity.
Perfume free. 30 ml.
-
farewell aging skin: farewell aging skin is enriched with Hyaluronic Acid, Madecassoside, Vitamin C, Marine ferment extract and a plant-derived Retinol alternative to hydrate the skin and improve suppleness and firmness while effectively reducing the signs of aging.
Perfume free. 30 ml.
-
farewell oily skin: Formulated especially for oily and acne-prone skin, farewell oily skin contains a zinc complex and plankton extract to reduce blemishes and clogged pores, while diminishing the facial sebum production. Niacinamide and Wintergreen leaf extract regenerate the skin barrier for a softer skin and a glowing complexion.
Perfume free. 30 ml.
farewell follows clean beauty concept
More and more people attach great importance to responsible consumption. Croma farewell™ complies with this wish – all serums are vegan, free from silicones, perfumes, mineral oils and are developed and produced exclusively in Austria. The products are cruelty-free and contain no animal-derived ingredients.
Price and availability
The Croma farewell™ facial serums are available soon via the Croma skincare web shop www.cromaskincareshop.com
and selected partners.
Recommended retail price: EUR 119,-.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210531005179/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SuperElastic* Material Unveiled by Angelalign2.11.2026 18:46:00 CET | Press release
New, Improved Clear Aligner Material Gives Orthodontists More Control Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other tre
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition2.11.2026 18:00:00 CET | Press release
The Company will hold an Extraordinary General Meeting on December 3, 2026 to further reinforce its Board of DirectorsAd hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity. Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course. The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside expertise span
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 15:35:00 CET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 15:00:00 CET | Press release
Companies to co-develop AI features, starting with physician documentation support, to enhance medicalforce and SBC Medical’s in-house systems and drive per-clinic productivity and profitability SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key HighlightsProven platform: medicalforce is used by more than 800 clinics*1 in J
Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 15:00:00 CET | Press release
The new offering brings together planning, performance benchmarks, headroom analysis and incrementality signals to help marketers make more informed decisions across the campaign lifecycle Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contribu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom